Jemperli (dostarlimab-gxly)
Endometrial Cancer, Mismatch Repair-Deficient Solid Tumors
ApprovedOut-Licensed (Royalty Asset)
Key Facts
Indication
Endometrial Cancer, Mismatch Repair-Deficient Solid Tumors
Phase
Approved
Status
Out-Licensed (Royalty Asset)
Company
About AnaptysBio
AnaptysBio is a clinical-stage biotech advancing a pipeline of best-in-class antibodies designed to dampen inflammatory responses and restore immune balance in autoimmune and inflammatory diseases. The company has demonstrated its antibody discovery capabilities through out-licensed assets like Jemperli (GSK) and imsidolimab (Vanda Pharmaceuticals), which provide royalty revenue. Strategically, AnaptysBio has announced its intent to separate its biopharma operations from its royalty assets by year-end 2026, aiming to create two distinct investment vehicles focused on development and financial assets, respectively.
View full company profile